Linvoseltamab (REGN5458) is a bispecific BCMA/CD3 T cell engaging antibody.
| SparkCures ID | 351 |
|---|---|
| Developed By | Regeneron Pharmaceuticals |
| Generic Name | Linvoseltamab (REGN5458) |
| Treatment Classifications | |
| Treatment Targets |
View all active clinical trials around the US.
The following is a listing of clinical trials for patients with multiple myeloma who have been newly diagnosed or have not yet received treatment.
The following is a listing of clinical trials for patients with multiple myeloma who have received one to two prior lines of therapy.
The following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.
The following is a listing of clinical trials for patients with Smoldering Myeloma.
September 29, 2023
The objective response rate (ORR) for 200mg linvoseltamab was 71%, with 59% and 30% of patients achieving very good partial response (VGPR) and complete responses (CR), respectively.
Treatment-emergent adverse effects included cytokine release syndrome, neutropenia (low white blood cell count), cough and others. However, these were mild to moderate in severity.